Investment in ORTHOREBIRTH株式会社 and acquisition of life-sciences expertise
First written in FY2018. 9 of 14 entries say "Restated". Latest entry: FY2024-Q3.
Dexerials moved to the "Worse" side of this theme in 2022.
0 other companies' latest entry also says "Other".
- FY2024-Q3Removed from the equity-method scope following the sale of all sharesAnnual report
「During the third quarter of the current consolidated fiscal year, we sold all shares held in ORTHOREBIRTH株式会社, formerly an equity-method affiliate, and excluded the company from the scope of application of the equity method.」
The Company sold all shares held in ORTHOREBIRTH株式会社 and excluded the company from the scope of application of the equity method. - FY2023MaterialisedAnnual report
「The loss on valuation of shares in an affiliate recorded as an extraordinary loss resulted from the impairment of shares in an equity-method affiliate.」
A loss on valuation of shares in an affiliate of ¥33 million was recorded for shares in an equity-method affiliate, and losses associated with investments in affiliates continued. - FY2022WorsenedAnnual report
「In the current consolidated fiscal year, the Group recognized an impairment loss on goodwill related to these shares, and the impairment loss is included in the equity-method investment loss of ¥431 million.」
The Company recognized an impairment loss on goodwill related to an equity-method affiliate, resulting in an equity-method investment loss of ¥431 million. - FY2022-Q3RestatedAnnual report
「Equity-method investment loss 125」
An equity-method investment loss of ¥125 million related to an equity-method affiliate was recorded for the nine months ended the third quarter, continuing the recognition of losses associated with investments in affiliates. - FY2022-Q2RestatedAnnual report
「Equity-method investment loss 87」
An equity-method investment loss of ¥87 million related to an equity-method affiliate was recorded for the six months ended the second quarter, continuing the recognition of losses associated with investments in affiliates. - FY2022-Q1RestatedAnnual report
「Equity-method investment loss 38」
An equity-method investment loss of ¥38 million related to an equity-method affiliate was recorded in the first quarter, continuing the recognition of losses associated with investments in affiliates. - FY2021RestatedAnnual report
「Ordinary income was ¥10,844 million, up 146.8% from the previous consolidated fiscal year, mainly due to the recording of an equity-method investment loss of ¥207 million.」
Losses related to equity-method affiliates, including ORTHOREBIRTH株式会社, continued to be recorded, reaching ¥207 million for the full fiscal year. - FY2021-Q2RestatedAnnual report
「Ordinary profit was ¥4,697 million, up 61.4% year on year, due to the recording of a foreign exchange gain, partly offset by the recording of an equity-method investment loss and other factors.」
An equity-method investment loss of ¥116 million was recorded for the six months ended the second quarter, and losses related to equity-method affiliates continued to be recognized. - FY2020RestatedAnnual report
「This resulted in ¥4,393 million, up 12.6% from the previous consolidated fiscal year, mainly due to the recording of an equity-method investment loss of ¥261 million.」
The classification of ORTHOREBIRTH株式会社 as an equity-method affiliate was reflected for the full fiscal year, and an equity-method investment loss of ¥261 million was recorded. - FY2020-Q3RestatedAnnual report
「Following the additional acquisition of shares in ORTHOREBIRTH株式会社, the company has been included in the scope of application of the equity method from the first quarter of the current consolidated fiscal year. The change in the scope of application of the equity method is expected to have a material impact on the consolidated financial statements for the consolidated fiscal year containing the current first quarter, including a decrease in investments and other assets on the consolidated balance sheet and an increase in non-operating expenses on the consolidated income statement.」
The classification of ORTHOREBIRTH株式会社 as an equity-method affiliate continued to be reflected, and an equity-method investment loss of ¥188 million was recorded for the nine months ended the third quarter. - FY2020-Q2RestatedAnnual report
「Following the additional acquisition of shares in ORTHOREBIRTH株式会社, the company has been included in the scope of application of the equity method from the first quarter of the current consolidated fiscal year. The change in the scope of application of the equity method is expected to have a material impact on the consolidated financial statements for the consolidated fiscal year containing the current first quarter, including a decrease in investments and other assets on the consolidated balance sheet and an increase in non-operating expenses on the consolidated income statement.」
The classification of ORTHOREBIRTH株式会社 as an equity-method affiliate continued to be reflected, and an equity-method investment loss of ¥129 million was recorded for the six months ended the second quarter. - FY2020-Q1RestatedAnnual report
「Because we additionally acquired shares of ORTHOREBIRTH株式会社 in April 2019, the company has been included in the scope of application of the equity method from the first quarter of the current consolidated fiscal year.」
The classification of ORTHOREBIRTH株式会社 as an equity-method affiliate was reflected in accounting from the first quarter, and an equity-method investment loss of ¥54 million was recorded. - FY2019AdvancedAnnual report
「April 2019: ORTHOREBIRTH株式会社 became an equity-method affiliate following the additional acquisition of shares」
ORTHOREBIRTH株式会社, an existing investee, became an equity-method affiliate following the additional acquisition of shares. - FY2018First statedAnnual report
「In March 2018, the Company invested in the biotech venture ORTHOREBIRTH株式会社. The company develops cotton-like artificial bone-filling materials made primarily from ceramics and polymer materials. The businesses have a high degree of technological compatibility, allowing us to provide support such as development assistance, while we seek to acquire marketing and other expertise to support growth in the life-sciences field.」
The Company invested in a biotech venture and outlined a policy of pursuing growth in life sciences through development support and the acquisition of marketing expertise.